Approved
Targeted Therapy

Evérolimus (VOTUBIA®)

Primo-indication

Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated.

Intervention Type

Pharmaceutical

Solid/Hematological

Solid

Cancer Type

Brain, Central Nervous System

Therapy Types

Targeted Therapy

Regulatory

FDA

N/A

Regulatory Pathway: n/a

EMA

02.09.2011

Regulatory Pathway: conditional approval

Availability in other countries

N/A

Focus Area

Cancer

ASMR

II

Medical Need

Unmet

SMR

IMPORTANT

Orphan Status

Yes

Other resources